# A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

> **NCT01848561** · — · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 8250 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01848561
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-04-29
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 8250 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848561, "A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01848561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*